Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells

Idelalisib is a targeted agent that potently inhibits PI3Kδ which is exclusively expressed in hematological cells. Bendamustine is a well-tolerated cytotoxic alkylating agent which has been extensively used for treatment of chronic lymphocytic leukemia (CLL). Both these agents are FDA-approved for C...

Descripción completa

Detalles Bibliográficos
Autores principales: Modi, Prexy, Balakrishnan, Kumudha, Yang, Qingshan, Wierda, William G., Keating, Michael J., Gandhi, Varsha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369961/
https://www.ncbi.nlm.nih.gov/pubmed/28187444
http://dx.doi.org/10.18632/oncotarget.15180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369961/
https://www.ncbi.nlm.nih.gov/pubmed/28187444
http://dx.doi.org/10.18632/oncotarget.15180

Ejemplares similares